


**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (Currently Amended) A method for treating a symptom of [[MCI]] mild cognitive impairment (MCI) comprising administering to a ~~mammal~~ human in need of such therapy, an effective amount of a compound of formula (I)



(I)

wherein R is (C<sub>1</sub>-C<sub>4</sub>)alkyl; or a pharmaceutically acceptable salt thereof.

Claim 2 (Currently Amended) The method of claim 1 wherein the symptom of MCI is [[an]] selected from the group consisting of: impairment of memory function compared to one's age cohort; memory impairment that is at least one standard deviation below that of a subject's peers, but without significant impairment in activities of daily living; reduced medial lobe volume; delayed recall tasks [[or]] in response to verbal and nonverbal stimuli; [[a]] decline in linguistic function or verbal fluency; ~~or~~ and impairment in a single cognitive domain other than the cognitive domain(s) responsible for memory.

Claim 3 (Currently Amended) The method of claim 1 wherein the symptom of MCI is the progression from MCI to [[AD]] Alzheimer's Disease (AD).

Claim 4 (Original) The method of claim 1 wherein the symptom of MCI is a symptom other than the progression from MCI to AD.

Claim 5 (Original) The method of claim 3 wherein the rate of progression from MCI to AD is reduced by at least 10 percent.

Claim 6 (Original) The method of claim 3 wherein the rate of progression from MCI to AD is reduced by at least 20 percent.

Claim 7 (Original) The method of claim 3 wherein the rate of progression from MCI to AD is reduced by at least 50 percent.

Claim 8 (Previously Presented) The method of claim 1 wherein the compound is  $\text{C}_6\text{H}_5\text{CH}_2\text{—C(=O)—L-Pro-Gly-OC}_2\text{H}_5$ , or a pharmaceutically acceptable salt thereof.

Claims 9-16 (Previously Canceled)